Gynecomastia: Hormonal Causes of Male Breast Tissue
An enlargement of the breast gland in men often feels embarrassing. Yet it rarely reflects a failure. Almost always it reflects a shifted ratio between estrogen and testosterone. Once you understand this balance, the causes become clearer, and you know when it is worth getting checked.
Men who come to me with an enlarged chest often carry more shame than symptoms. Let me give you something right at the start: gynecomastia is not a sign of too little masculinity. It is usually the simple result of estrogen and testosterone falling out of balance at the breast gland. That can have many reasons, from puberty to weight to medications. The good news: precisely because it is a ratio, there are more points to start from than just turning a single number.
Maybe you first noticed it at the gym, or in the mirror, or through a pulling feeling behind the nipple. The chest looks fuller, softer, more feminine. And right away the inner commentary kicks in: is something wrong with my hormones? That question is valid, but the answer is usually more nuanced than many people think. Because it is not primarily about whether your testosterone is low. It is about the ratio between two hormones.
In this article we look together at what lies behind male breast tissue. We understand why the ratio of estrogen to testosterone is the key, what role the enzyme aromatase and fatty tissue play, how the liver and medications come into it, why puberty is a special case, and how you can tell when gynecomastia belongs in a medical evaluation. The goal is not fear, but clarity.
What gynecomastia really is, and what it is not
Let us start with the definition, because this is where most misunderstandings arise. Gynecomastia is the benign increase of true glandular tissue in the male breast. On palpation you find a firm core of tissue directly behind the nipple. This is distinct from lipomastia, sometimes called pseudogynecomastia, where only soft fat makes the chest look larger without true gland having grown. In practice, the two often occur mixed.
The framing matters right from the start: gynecomastia is very common, usually harmless, and not a precursor of breast cancer. Male breast cancer is rare and has a different feel on examination, often hard, one-sided, and off-center. That is precisely why looking closely is worthwhile, so the rare serious findings are not missed.
Common, benign, but often with a cause in adulthood
Consensus guideline George Kanakis and colleagues published the European Academy of Andrology guideline on gynecomastia in Andrology in 2019. They put the prevalence at roughly 32 to 65 percent, depending on age and definition. Gynecomastia of infancy and puberty usually regresses on its own. In adulthood, by contrast, a careful evaluation can reveal an underlying cause in about 45 to 50 percent of cases. The guideline stresses that gynecomastia is not considered a precursor of breast cancer, and recommends a targeted search for treatable causes rather than premature treatment.
Kanakis GA, Nordkap L, Bang AK, et al. Andrology. 2019;7(6):778-793. doi:10.1111/andr.12636 · PMID: 31099174
Gynecomastia is not a defect of your masculinity. It is a signal that the ratio of two hormones has tipped at a sensitive place. In many men the cause is harmless and temporary. In some, it points to something that can be treated well. In both cases it is not a reason for shame, but a good reason to take a closer look.
The core: the ratio of estrogen to testosterone
This is where the real key to understanding lies. The breast gland responds to two opposing signals. Estrogen stimulates glandular growth. Testosterone counteracts it and slows it down. As long as both are in balance, the male chest stays flat. When the ratio tips toward estrogen, the gland can begin to grow. So what is decisive is not a single hormone value, but the balance.
This ratio can get out of step in several ways. More estrogen can be produced, for example through more conversion in fatty tissue. Less testosterone can be present, for example with underactive testes. Medications can block the testosterone receptor so that the testosterone present does not get through. And the breast gland itself can respond with different sensitivity. It is precisely this variety that explains why a single laboratory number often does not explain gynecomastia.
An older study from 1990 illustrated this point strikingly. In men with liver cirrhosis, the ratio of estrogen to free testosterone was markedly elevated. But, and this is the instructive part, this ratio barely differed between men with and without palpable gynecomastia. The authors concluded that besides the hormone ratio, other factors play a part, such as how sensitively the breast gland responds to the shifted ratio.
The hormone ratio is shifted, but does not explain everything
Case-control, n=36 James Cavanaugh and colleagues compared 18 men with advanced liver cirrhosis to 18 lean, age-matched controls in the Archives of Internal Medicine in 1990. In the cirrhosis patients, free testosterone was lower and the ratio of total estrogen to free testosterone was about four times as high. Notably, this ratio did not differ substantially between men with and without gynecomastia. This suggests that the shifted ratio can be a precondition, while the individual sensitivity of the breast gland co-determines whether a visible gynecomastia results.
Cavanaugh J, Niewoehner CB, Nuttall FQ. Arch Intern Med. 1990;150(3):563-565. PMID: 2310274 · DOI: not assigned (print 1990)
Four cellular levels at which the balance tips
In clinical psychoneuroimmunology, or PNI for short, we look not only at the testes, but at the networked system. In gynecomastia too, several levels interlock. Each card describes one mechanism at the cellular level that can shift the ratio of estrogen to testosterone.
Fatty tissue and aromatase
The enzyme aromatase sits in fatty tissue. At the cellular level it converts testosterone into estrogen. The more fat mass, the more of this conversion. So obesity can shift the ratio noticeably toward estrogen and at the same time, through stored chest fat, make the chest look fuller. Fatty tissue is therefore not a passive store but an active hormone organ that, in men, helps determine the chest picture.
Liver and hormone breakdown
The liver helps break down sex hormones and so maintains the balance. At the cellular level, liver enzymes metabolize estrogens and androgens. If the liver is burdened by cirrhosis or by alcohol, this breakdown can be impaired, and the ratio can shift. The binding protein SHBG, which is made in the liver, also influences how much free, that is, active, hormone is available.
Receptor and medications
Some medications act directly at the switching point of the cell. Antiandrogens occupy the testosterone receptor, so that the testosterone present can no longer send its braking signal. Other substances raise estrogen or prolactin. At the cellular level, what counts in the end is not only how much hormone circulates in the blood, but whether the signal reaches the breast gland at all. That is why medications can trigger gynecomastia without changing the blood value much.
Testes and control
The hypothalamus and pituitary send the signal via LH to the testes to produce testosterone. If this control fails or the testes produce too little, testosterone falls and the ratio tips. An elevated prolactin or an overactive thyroid can also act at this level. This is why the evaluation, besides estrogen and testosterone, also keeps an eye on the control hormones.
These four levels explain why two men with the same testosterone value can look quite different. And now you know why a good evaluation is more than a single blood draw.
Obesity and aromatase: the most common lever
If there is one factor that plays an especially common role in gynecomastia in everyday practice, it is body weight. This has two reasons that act together. First, fatty tissue contains aromatase, which converts testosterone into estrogen, so the ratio slides toward estrogen. Second, the stored fat in the chest makes for a fuller picture, even without true glandular growth. True gynecomastia and lipomastia overlap here.
Interestingly, the link does not appear equally strong in every study. One South Korean analysis of computed tomography scans, for example, found no clear link between body mass index and the gynecomastia measured on the image, but did find clear connections to chronic liver and kidney disease and to medications. This fits the overall picture: weight is an important factor, but not the only one.
Gynecomastia links to liver, kidney, and medications
Cross-sectional, retrospective Min Seon Kim and colleagues analyzed the chest CTs of 5,501 men in the American Journal of Men's Health in 2020. Gynecomastia was found in 12.7 percent. The age distribution showed two peaks, one in the 20 to 29 year olds and one in those over 70. Statistically, gynecomastia was linked to chronic liver disease, all stages of chronic kidney disease, and to medications, but not to body mass index. The authors conclude that a gynecomastia detected on imaging can justify further evaluation for a treatable cause.
Kim MS, Kim JH, Lee KH, Suh YJ. Am J Mens Health. 2020;14(3):1557988320908102. doi:10.1177/1557988320908102 · PMID: 32456508
From this follows a sober framing. In many men with obesity, a mixture of lipomastia and true gynecomastia is likely, and a sustained weight loss can favorably influence the picture. At the same time, a newly appeared, one-sided, or painful enlargement should not be hastily blamed on weight. And now you know why weight is often the first lever, but rarely the only one.
Medications, liver, and anabolic steroids
A significant share of gynecomastia in adulthood goes back to medications. Estimates assign them a relevant proportion of cases. The mechanisms differ, the result is similar: the ratio of estrogen to testosterone shifts, or the testosterone signal no longer reaches the breast gland.
Which medications are well documented to be linked to gynecomastia
Evidence review Fnu Deepinder and Glenn Braunstein assessed the evidence on drug-induced gynecomastia in Expert Opinion on Drug Safety in 2012. They estimate that medications cause about 10 to 25 percent of all cases. Substances considered definitely linked include spironolactone, cimetidine, ketoconazole, growth hormone, estrogens, hCG, antiandrogens, GnRH analogs, and 5-alpha-reductase inhibitors. Probably linked, they list risperidone, certain blood pressure drugs, omeprazole, anabolic steroids, alcohol, and opioids, among others. They also stress that many older reports are methodologically weak.
Deepinder F, Braunstein GD. Expert Opin Drug Saf. 2012;11(5):779-795. doi:10.1517/14740338.2012.712109 · PMID: 22862307
A systematic review with meta-analysis quantified this link for several drug classes. It found a markedly increased risk with antiandrogens, an increased risk with 5-alpha-reductase inhibitors and with spironolactone. The authors explain the effect through a change in the ratio of testosterone to estradiol, and for psychiatric drugs additionally through raised prolactin (doi:10.4081/aiua.2021.4.489, PMID: 34933535).
The liver deserves a mention of its own here. It helps break down sex hormones. A study of human liver tissue showed that enzymes which convert active estradiol into an inactive form are present in the liver, and that with liver damage the total amount of functioning liver cells falls, which can impair hormone breakdown (doi:10.1507/endocrj.47.697, PMID: 11228044). This explains mechanistically why advanced liver disease can go together with gynecomastia.
"If I take testosterone or anabolic steroids, my chest will get flatter." The opposite can happen. Anyone who supplies a lot of testosterone or anabolic steroids from the outside gives the body more raw material that can be converted into estrogen via aromatase. So the very attempt to become more masculine can trigger breast gland enlargement. This is not a moral judgment, it is plain biochemistry.
Anabolic steroids change breast tissue and increase revision surgery
Cohort, retrospective Miliana Vojvodic and colleagues analyzed 964 gynecomastia operations in the Annals of Plastic Surgery in 2019. Eleven percent of patients had used anabolic-androgenic steroids. These users were older at onset and surgery, had a higher body mass index, more often a bodybuilding background, and a different ratio of glandular to fatty tissue in the breast. They also needed revision surgeries significantly more often. This suggests that substance use changes the breast tissue and can make treatment more difficult.
Vojvodic M, Xu FZ, Cai R, Roy M, Fielding JC. Ann Plast Surg. 2019;83(3):258-263. doi:10.1097/SAP.0000000000001850 · PMID: 31021838
Puberty and adulthood: two different stories
One of the most important distinctions of all is by age. Because gynecomastia means something different in an adolescent than in a middle-aged man. Confusing the two leads either to needless worry or to missing the essential point.
In puberty, gynecomastia is usually a temporary developmental phenomenon. In this phase, estrogen often rises earlier and faster than testosterone, so the ratio briefly tips toward estrogen. When testosterone catches up, the gland regresses on its own in the vast majority of cases. The European Academy of Andrology guideline describes that pubertal gynecomastia affects about half of boys in mid-puberty and regresses on its own in more than ninety percent of cases within about 24 months.
Even in special constellations, patience is often sensible
Cohort, prospective Gary Butler studied the incidence of pubertal gynecomastia in boys with Klinefelter syndrome in the European Journal of Pediatrics in 2021 and compared it to healthy controls. Remarkably, the incidence at about 35 percent was no higher than in typically developing boys. This underlines how widespread the pubertal form is in general. In the affected boys with proven underactive testes, the gynecomastia regressed in most cases under early, carefully dosed testosterone treatment.
Butler G. Eur J Pediatr. 2021;180(10):3201-3207. doi:10.1007/s00431-021-04083-2 · PMID: 33934233
In adulthood, the threshold for evaluation is lower. Here a careful search according to guidelines can find a cause in about half of cases. A newly appeared gynecomastia without a clear trigger, especially if it grows quickly or is painful, should therefore not simply be left to wait, but assessed by a doctor. The aim is not to miss treatable causes such as medications, thyroid, liver, or rarely a hormone-producing tumor.
Three levers that can support the balance
Before turning to hormones, it is worth looking at what co-determines the ratio in the background. These three levers are a starting point and worth a conversation, not a treatment plan. The individual path is found with medical guidance that first clarifies the cause.
Look at weight and chest fat
Because fatty tissue converts testosterone into estrogen via aromatase, a sustained weight loss can favorably influence the ratio and at the same time reduce the stored chest fat. This is not about a crash diet, but about a way of eating that keeps blood sugar calm, with enough protein and fiber. This can make a visible difference, especially in the mixed form of lipomastia and gland.
Review your medications with medical help
If a gynecomastia coincides in time with a new medication, there could be a connection. But never stop a prescribed drug on your own. Discuss your observation with the doctor who prescribed it. Sometimes there is an alternative, sometimes the benefit of the medication outweighs it. This weighing belongs in medical hands, not in a self-decision.
Take the liver and alcohol seriously
Because the liver helps break down sex hormones, a mindful approach to alcohol can ease the hormone balance. Persistent, high alcohol consumption can shift the ratio toward estrogen on several pathways. This is not a moral appeal, but a pointer to a real mechanism. Whoever changes something here supports not only the chest, but the whole metabolism.
And if the enlargement remains despite good foundations, if it appears new, grows quickly, is painful, or is one-sided and hard, then a targeted evaluation belongs to it. It usually includes a conversation, palpation of breast and testes, and selected laboratory values. This helps find treatable causes and recognize the rare serious findings. A good evaluation takes your worry seriously without stoking panic.
It is not about a number, it is about a ratio
Your chest does not tell of too little masculinity. It tells that estrogen and testosterone have fallen out of balance at a sensitive place. Precisely because it is a balance, there are ways to understand it and, with medical guidance, to influence it. The first step is not shame, but clarity about where the shift comes from.
Frequently asked questions about gynecomastia
What exactly is gynecomastia?
Gynecomastia is a benign enlargement of the true breast gland in men. On examination you can feel a firm, often disc-shaped core of tissue directly behind the nipple. That is different from so-called lipomastia or pseudogynecomastia, where only soft fatty tissue makes the chest look larger. Gynecomastia is very common. Guidelines put the prevalence at roughly one to two thirds of men, depending on age and definition. Important context: gynecomastia is not a precursor of breast cancer. It is usually harmless, but in some cases it can be a sign of a treatable cause, which is why it is worth having it looked at by a doctor.
What hormonal cause lies behind gynecomastia?
The common denominator of almost all forms is a shifted ratio between estrogen and testosterone at the level of the breast gland. Estrogen stimulates glandular growth, testosterone counteracts it. So what matters is not a single value, but the balance between the two. This balance can tip in several ways: through more estrogen production, through less testosterone, through medications that interfere at the receptor, or through a changed sensitivity of the breast gland itself. That is why it is rarely enough to look only at testosterone. It is about the whole ratio.
What does aromatase have to do with male breast tissue?
Aromatase is an enzyme that converts testosterone into estrogen. It sits especially in fatty tissue. The more fat mass a man carries, the more testosterone can be converted into estrogen. This is one reason why obesity is so closely linked to gynecomastia. More abdominal and chest fat means more aromatase activity and therefore a ratio that shifts toward estrogen. In lipomastia, the fat also plays a purely visual role. In practice, true glandular enlargement and pure fat deposition are often mixed.
Why do so many boys develop gynecomastia during puberty?
Pubertal gynecomastia is very common and harmless in the vast majority of cases. According to guidelines it affects about half of boys in mid-puberty. The reason is a temporary imbalance: in this phase estrogen rises earlier and faster than testosterone, so the ratio briefly tips toward estrogen. Once testosterone catches up, the breast gland regresses on its own in more than ninety percent of cases within about two years. That is why watchful waiting is usually the right path here. If the enlargement is very pronounced or persists for a long time, a medical evaluation makes sense.
Which medications can trigger gynecomastia?
Medications are considered the cause of a significant share of cases. The link is reasonably well documented for spironolactone, certain acid blockers such as cimetidine, the antifungal ketoconazole, antiandrogens used in prostate cancer treatment, 5-alpha-reductase inhibitors, and some psychiatric drugs, among others. The mechanisms differ: some drugs block the testosterone receptor, others raise estrogen or prolactin. Important: never stop a prescribed medication on your own. If you suspect a connection, discuss it with the doctor who prescribed it.
Can the liver be involved in gynecomastia?
Yes, the liver plays a central role in hormone metabolism, because it helps break down sex hormones. In advanced liver disease such as cirrhosis, the ratio of estrogen to testosterone can shift. Studies in men with liver cirrhosis show lower free testosterone levels and a markedly higher ratio of estrogen to free testosterone. At the same time, the same data show that the ratio alone does not explain everything, because men without gynecomastia had similar values. Alcohol can also act on several pathways here. A newly appeared gynecomastia therefore belongs in a medical assessment.
Do anabolic steroids and testosterone preparations play a role?
Yes, and this is a frequently underestimated point. Anyone who supplies anabolic steroids or high doses of testosterone from the outside gives the body more raw material that can be converted into estrogen via aromatase. So paradoxically, the very attempt to become more masculine can trigger breast gland enlargement. In one surgical cohort, users of anabolic-androgenic steroids had a different breast tissue composition and more revision surgeries. This is not a moral judgment, it is biochemistry. It shows why these substances are problematic outside a clear medical indication.
How does gynecomastia differ in adolescents and adults?
In adolescents during puberty, gynecomastia is usually a temporary developmental phenomenon that regresses on its own. An extensive search for an illness is less often needed here. In adulthood the situation is different. Here a careful evaluation according to guidelines can find an underlying cause in about half of cases, such as obesity, medications, a thyroid or liver disease, or rarely a hormone-producing tumor. So the rule is: a newly appeared gynecomastia in adulthood without a clear trigger should be investigated more thoroughly than the typical pubertal form.
When should I see a doctor about gynecomastia?
You should have a breast enlargement checked by a doctor if it appears new and without an obvious reason, grows quickly, is one-sided and hard, is painful, comes with lumps, skin changes or discharge from the nipple, or comes with signs of underactive testes such as declining libido. Gynecomastia together with weight loss, yellowing of the skin, or new medications also belongs in an assessment. The examination usually includes a conversation, palpation of breast and testes, and often laboratory values. The aim is not panic, but recognizing treatable causes and the rare serious findings.
Does gynecomastia go away again?
That depends heavily on cause and duration. The pubertal form usually regresses on its own within about two years. If a trigger is removed, for example a medication is stopped or weight is reduced, fresh glandular tissue can regress. But the longer a gynecomastia persists, the more the tissue turns into firm connective tissue that barely regresses on its own. For long-standing, distressing gynecomastia, guidelines see surgery as the treatment of choice, while medications have a role only in certain situations. Which path fits is best clarified individually with a doctor.
All topics in the cluster "Hormone Guide (Men)"
This article is Spoke 9. Back to the pillar or on to a related topic.
- Male Hormones (overview/pillar)
- Testosterone is falling worldwide (each generation lower)
- Testosterone deficiency: symptoms in men
- Raising testosterone naturally
- Testosterone test: understanding your values
- TRT: testosterone replacement therapy
- Erectile dysfunction: causes
- Loss of libido in men
- Hypogonadism: forms and causes
- Gynecomastia: hormonal causes
- Sperm quality and fertility
- Testosterone boosters: what do they do
- Andropause: male menopause
- Micronutrients for testosterone
- DHT, hair loss and testosterone
- Estrogen in men and aromatase
- Cortisol, stress, sleep and testosterone
- Obesity, insulin and testosterone
- Xenoestrogens in men
- Sport, strength training and testosterone
- Prolactin and thyroid in men
Connections to other topics
A low testosterone shifts the ratio toward estrogen. The deeper framing of when a low value really is a deficiency.
How estrogen, progesterone, and testosterone work together as a networked system, with parallels to the balance in men.
The stress axis is tightly interwoven with the control of sex hormones and can indirectly move the balance.
Iron deficiency amplifies many complaints that look like a pure hormone problem, from exhaustion to reduced stamina.
An overactive thyroid can help trigger a gynecomastia. Why a look at the thyroid is worthwhile.
Through the immune system and silent inflammation, the gut helps shape how well your hormone balance stays in equilibrium.
Sources and further reading
- Kanakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology. 2019;7(6):778-793. doi:10.1111/andr.12636 · PMID: 31099174 [Consensus Guideline]
- Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012;11(5):779-795. doi:10.1517/14740338.2012.712109 · PMID: 22862307 [Review]
- Trinchieri A, Perletti G, Magri V, et al. Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials. Arch Ital Urol Androl. 2021;93(4):489-496. doi:10.4081/aiua.2021.4.489 · PMID: 34933535 [Meta-analysis]
- Cavanaugh J, Niewoehner CB, Nuttall FQ. Gynecomastia and cirrhosis of the liver. Arch Intern Med. 1990;150(3):563-565. PMID: 2310274 [Case-Control]
- Kim MS, Kim JH, Lee KH, Suh YJ. Incidental Gynecomastia on Thoracic Computed Tomography in Clinical Practice. Am J Mens Health. 2020;14(3):1557988320908102. doi:10.1177/1557988320908102 · PMID: 32456508 [Cohort]
- Vojvodic M, Xu FZ, Cai R, Roy M, Fielding JC. Anabolic-androgenic Steroid Use Among Gynecomastia Patients: Prevalence and Relevance to Surgical Management. Ann Plast Surg. 2019;83(3):258-263. doi:10.1097/SAP.0000000000001850 · PMID: 31021838 [Cohort]
- Butler G. Incidence of gynaecomastia in Klinefelter syndrome adolescents and outcome of testosterone treatment. Eur J Pediatr. 2021;180(10):3201-3207. doi:10.1007/s00431-021-04083-2 · PMID: 33934233 [Cohort]
- Narasaka T, Moriya T, Endoh M, et al. 17Beta-hydroxysteroid dehydrogenase type 2 and dehydroepiandrosterone sulfotransferase in the human liver. Endocr J. 2000;47(6):697-705. doi:10.1507/endocrj.47.697 · PMID: 11228044 [Pathophysiology]
- Baumgarten L, Dabaja AA. Diagnosis and Management of Gynecomastia for Urologists. Curr Urol Rep. 2018;19(7):46. doi:10.1007/s11934-018-0796-x · PMID: 29774423 [Review]
- Dobs A, Darkes MJM. Incidence and management of gynecomastia in men treated for prostate cancer. J Urol. 2005;174(5):1737-1742. doi:10.1097/01.ju.0000176461.75794.f8 · PMID: 16217274 [Review]
- Patanè FG, Liberto A, Maria Maglitto AN, et al. Nandrolone Decanoate: Use, Abuse and Side Effects. Medicina (Kaunas). 2020;56(11):606. doi:10.3390/medicina56110606 · PMID: 33187340 [Systematic Review]